ATON Group

ATON Group, rebranded from Hybrigenics in 2025, is a Paris-headquartered organization that functions as an integrated life science accelerator and service provider. It leverages a portfolio of cutting-edge technology platforms—spanning preclinical/clinical services, monoclonal antibody production, laboratory equipment, and human tissue provision—to drive a fundamental shift toward personalized medicine. The company's strategy is to create, support, and energize next-generation life science companies, aiming to make drug development more efficient, effective, and patient-centric. ATON targets a future where therapies are precisely adapted to individual patient biology.

Integrated ecosystem of four synergistic platforms: 1) Preclinical & Clinical Services for accelerated drug development, 2) Bcell Design for monoclonal antibody production, 3) Proprietary Laboratory Equipment for high-sensitivity analysis, and 4) Ethical Human Tissue Provision.

ATON competes across multiple segments: against large, full-service CROs (e.g., IQVIA, LabCorp) in services, specialized antibody companies (e.g., Abcam), and equipment manufacturers. Its differentiated strategy is to combine these elements into a cohesive, biology-focused ecosystem, a niche not fully occupied by larger, more siloed competitors.